Report cover image

Encephalitis Treatment Market Forecasts to 2032 – Global Analysis By Disease Type (Primary encephalitis and Secondary encephalitis), Route of Administration, Causative Agent, Distribution Channel, End User and By Geography

Publisher Stratistics Market Research Consulting
Published Jul 07, 2025
Length 200 Pages
SKU # SMR20173790

Description

According to Stratistics MRC, the Global Encephalitis Treatment Market is accounted for $23.9 billion in 2025 and is expected to reach $38.9 billion by 2032 growing at a CAGR of 7.2% during the forecast period. Encephalitis treatment refers to the medical management and therapeutic interventions used to address encephalitis, an inflammation of the brain typically caused by viral infections, though bacterial, fungal, or autoimmune causes are also possible. Treatment aims to reduce brain inflammation, manage symptoms, and prevent complications. It often includes antiviral or antibiotic medications, corticosteroids to reduce swelling, anticonvulsants for seizures, and supportive care such as hydration and oxygen therapy. In severe cases, hospitalization and intensive care may be necessary. Early diagnosis and prompt treatment are crucial to minimize long-term neurological damage and improve patient outcomes, especially in vulnerable populations such as children and the elderly.

According to the National Center for Vector Borne Diseases Control, Japanese encephalitis is a significant health concern in India.

Market Dynamics:

Driver:

Rising Incidence of Viral Encephalitis

The rising incidence of viral encephalitis is positively impacting the encephalitis treatment market by driving demand for advanced diagnostic tools, antiviral therapies, and supportive care solutions. Increasing awareness and early diagnosis are pushing healthcare providers to invest in better treatment protocols, boosting market growth. Moreover, governments and healthcare institutions are funding research and development efforts to improve treatment efficacy. This growing focus on timely and effective management of encephalitis is encouraging pharmaceutical companies to innovate, further expanding the market landscape.

Restraint:

High Cost of Treatment

The high cost of encephalitis treatment significantly hampers market growth, especially in low- and middle-income regions. Expensive antiviral medications, intensive care, prolonged hospitalization, and rehabilitation services place a financial burden on patients and healthcare systems. This deters timely diagnosis and treatment, leading to delayed interventions and poor outcomes. As a result, the affordability barrier restricts access to advanced treatment options, limiting market expansion and posing a major challenge to healthcare providers.

Opportunity:

Advancements in Diagnostics & Therapeutics

Advancements in diagnostics and therapeutics are significantly driving growth in the market. The development of rapid and accurate diagnostic tools enables early detection, improving treatment outcomes. Innovations in antiviral and immunomodulatory therapies are enhancing patient recovery rates and reducing long-term complications. Personalized medicine and biomarker-based treatments are further refining therapeutic approaches. These advancements not only improve clinical efficiency but also encourage greater investment in research, ultimately expanding the market and offering improved care for encephalitis patients globally.

Threat:

Complex Diagnosis

The complex and time-consuming process of diagnosing encephalitis poses a significant challenge to the treatment market. Delayed or inaccurate diagnosis can lead to postponed treatment, worsening patient outcomes and increasing the risk of complications. Limited access to advanced diagnostic tools, especially in low-resource settings, further hampers early detection. This complexity restricts market growth by increasing healthcare costs and deterring timely intervention, thereby impacting the overall effectiveness of encephalitis treatment solutions.

Covid-19 Impact

The COVID-19 pandemic disrupted the encephalitis treatment market by straining healthcare systems and diverting resources toward managing the virus. Delays in diagnosis, reduced hospital visits, and interruptions in clinical trials affected timely treatment. However, increased awareness of neurological complications linked to COVID-19 also led to a renewed focus on encephalitis research. This dual impact created both short-term challenges and long-term opportunities for advancements in encephalitis diagnostics and therapies.

The viral segment is expected to be the largest during the forecast period

The viral segment is expected to account for the largest market share during the forecast period, due to rising prevalence of viral infections such as herpes simplex, Japanese encephalitis, and West Nile virus. Increasing awareness and early diagnosis of viral encephalitis have boosted the demand for effective antiviral drugs and supportive therapies. Moreover, government initiatives and funding for vaccination and outbreak control contribute to market expansion. The urgency to manage viral outbreaks further accelerates research, development, and adoption of advanced encephalitis treatment options.

The antibiotics segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the antibiotics segment is predicted to witness the highest growth rate, as it offers effective solutions against bacterial causes of the disease, particularly in secondary encephalitis cases. Increased awareness among healthcare providers, advancements in targeted antibiotic therapies are driving demand. Additionally, the growing availability of broad-spectrum antibiotics and supportive diagnostic tools is enhancing timely treatment, reducing complications, and improving patient recovery rates. These factors collectively support market expansion and reinforce antibiotics as a critical component in encephalitis care strategies

Region with largest share:

During the forecast period, the Asia Pacific region is expected to hold the largest market share owing to rising healthcare awareness, increasing prevalence of viral infections, and improved access to advanced medical facilities. Government initiatives aimed at strengthening healthcare infrastructure and expanding immunization programs are further supporting market expansion. Additionally, increasing investments in R&D and the availability of effective antiviral therapies are contributing to enhanced treatment outcomes. The growing population and demand for better neurological care are also fueling the region’s market growth positively.

Region with highest CAGR:

Over the forecast period, the North America region is anticipated to exhibit the highest CAGR, because of growing awareness and an increase in encephalitis cases brought on by viral infections and illnesses spread by mosquitoes. Drug development and early diagnosis have increased because to strong government initiatives and research funding. The area gains by having access to cutting-edge technologies and being home to significant pharmaceutical enterprises. Furthermore, the market is expanding in the US and Canada due to rising need for efficient antiviral treatments and vaccinations.

Key players in the market

Some of the key players profiled in the Encephalitis Treatment Market include Pfizer Inc., Sanofi S.A., F. Hoffmann-La Roche Ltd., GlaxoSmithKline plc (GSK), Merck & Co., Inc., Teva Pharmaceutical Industries Ltd., Abbott Laboratories, Basilea Pharmaceutica Ltd., Melinta Therapeutics LLC, Bristol Myers Squibb, Novartis AG, Johnson & Johnson, Eli Lilly and Company, Takeda Pharmaceutical Company Limited, Pharma Limited, Hikma Pharmaceuticals PLC, Valneva SE, Bharat Biotech, BIKEN and Substipharm.

Key Developments:

In May 2025, Pfizer Inc. announced it has entered into an exclusive global, ex-China, licensing agreement with 3SBio, Inc., for the development, manufacturing and commercialization of SSGJ-707, a bispecific antibody targeting PD-1 and VEGF, currently undergoing several clinical trials in China for non-small cell lung cancer, metastatic colorectal cancer, and gynecological tumors.

In October 2024, TRIANA Biomedicines, Inc. announced that it has entered into a strategic collaboration and licensing agreement with Pfizer to discover novel molecular glue degraders for multiple targets in several disease areas, including oncology.

Disease Types Covered:
• Primary encephalitis
• Secondary encephalitis

Treatments Covered:
• Antiviral agents
• Steroid injections
• Antibiotics
• Immunoglobulin therapy
• Plasmapheresis
• Other Treatments

Route of Administrations Covered:
• Oral
• Parenteral
• Other Routes of Administration

Causative Agents Covered:
• Viral
• Autoimmune
• Bacterial
• Pathogens

Distribution Channels Covered:
• Hospital Pharmacies
• Online Pharmacies
• Retail Pharmacies

End Users Covered:
• Hospitals
• Research Centers
• Clinics
• Specialty Centers
• Other End Users

Regions Covered:
• North America
US
Canada
Mexico
• Europe
Germany
UK
Italy
France
Spain
Rest of Europe
• Asia Pacific
Japan
China
India
Australia
New Zealand
South Korea
Rest of Asia Pacific
• South America
Argentina
Brazil
Chile
Rest of South America
• Middle East & Africa
Saudi Arabia
UAE
Qatar
South Africa
Rest of Middle East & Africa

What our report offers:
- Market share assessments for the regional and country-level segments
- Strategic recommendations for the new entrants
- Covers Market data for the years 2022, 2023, 2024, 2026, and 2030
- Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
- Strategic recommendations in key business segments based on the market estimations
- Competitive landscaping mapping the key common trends
- Company profiling with detailed strategies, financials, and recent developments
- Supply chain trends mapping the latest technological advancements

Table of Contents

200 Pages
1 Executive Summary
2 Preface
2.1 Abstract
2.2 Stake Holders
2.3 Research Scope
2.4 Research Methodology
2.4.1 Data Mining
2.4.2 Data Analysis
2.4.3 Data Validation
2.4.4 Research Approach
2.5 Research Sources
2.5.1 Primary Research Sources
2.5.2 Secondary Research Sources
2.5.3 Assumptions
3 Market Trend Analysis
3.1 Introduction
3.2 Drivers
3.3 Restraints
3.4 Opportunities
3.5 Threats
3.6 End User Analysis
3.7 Emerging Markets
3.8 Impact of Covid-19
4 Porters Five Force Analysis
4.1 Bargaining power of suppliers
4.2 Bargaining power of buyers
4.3 Threat of substitutes
4.4 Threat of new entrants
4.5 Competitive rivalry
5 Global Encephalitis Treatment Market, By Disease Type
5.1 Introduction
5.2 Primary encephalitis
5.3 Secondary encephalitis
6 Global Encephalitis Treatment Market, By Treatment
6.1 Introduction
6.2 Antiviral agents
6.3 Steroid injections
6.4 Antibiotics
6.5 Immunoglobulin therapy
6.6 Plasmapheresis
6.7 Other Treatments
7 Global Encephalitis Treatment Market, By Route of Administration
7.1 Introduction
7.2 Oral
7.3 Parenteral
7.4 Other Routes of Administration
8 Global Encephalitis Treatment Market, By Causative Agent
8.1 Introduction
8.2 Viral
8.3 Autoimmune
8.4 Bacterial
8.5 Pathogens
9 Global Encephalitis Treatment Market, By Distribution Channel
9.1 Introduction
9.2 Hospital Pharmacies
9.3 Online Pharmacies
9.4 Retail Pharmacies
10 Global Encephalitis Treatment Market, By End User
10.1 Introduction
10.2 Hospitals
10.3 Research Centers
10.4 Clinics
10.5 Specialty Centers
10.6 Other End Users
11 Global Encephalitis Treatment Market, By Geography
11.1 Introduction
11.2 North America
11.2.1 US
11.2.2 Canada
11.2.3 Mexico
11.3 Europe
11.3.1 Germany
11.3.2 UK
11.3.3 Italy
11.3.4 France
11.3.5 Spain
11.3.6 Rest of Europe
11.4 Asia Pacific
11.4.1 Japan
11.4.2 China
11.4.3 India
11.4.4 Australia
11.4.5 New Zealand
11.4.6 South Korea
11.4.7 Rest of Asia Pacific
11.5 South America
11.5.1 Argentina
11.5.2 Brazil
11.5.3 Chile
11.5.4 Rest of South America
11.6 Middle East & Africa
11.6.1 Saudi Arabia
11.6.2 UAE
11.6.3 Qatar
11.6.4 South Africa
11.6.5 Rest of Middle East & Africa
12 Key Developments
12.1 Agreements, Partnerships, Collaborations and Joint Ventures
12.2 Acquisitions & Mergers
12.3 New Product Launch
12.4 Expansions
12.5 Other Key Strategies
13 Company Profiling
13.1 Pfizer Inc.
13.2 Sanofi S.A.
13.3 F. Hoffmann-La Roche Ltd.
13.4 GlaxoSmithKline plc (GSK)
13.5 Merck & Co., Inc.
13.6 Teva Pharmaceutical Industries Ltd.
13.7 Abbott Laboratories
13.8 Basilea Pharmaceutica Ltd.
13.9 Melinta Therapeutics LLC
13.10 Bristol Myers Squibb
13.11 Novartis AG
13.12 Johnson & Johnson
13.13 Eli Lilly and Company
13.14 Takeda Pharmaceutical Company Limited
13.15 Aurobindo Pharma Limited
13.16 Hikma Pharmaceuticals PLC
13.17 Valneva SE
13.18 Bharat Biotech
13.19 BIKEN
13.20 Substipharm
List of Tables
Table 1 Global Encephalitis Treatment Market Outlook, By Region (2024-2032) ($MN)
Table 2 Global Encephalitis Treatment Market Outlook, By Disease Type (2024-2032) ($MN)
Table 3 Global Encephalitis Treatment Market Outlook, By Primary encephalitis (2024-2032) ($MN)
Table 4 Global Encephalitis Treatment Market Outlook, By Secondary encephalitis (2024-2032) ($MN)
Table 5 Global Encephalitis Treatment Market Outlook, By Treatment (2024-2032) ($MN)
Table 6 Global Encephalitis Treatment Market Outlook, By Antiviral agents (2024-2032) ($MN)
Table 7 Global Encephalitis Treatment Market Outlook, By Steroid injections (2024-2032) ($MN)
Table 8 Global Encephalitis Treatment Market Outlook, By Antibiotics (2024-2032) ($MN)
Table 9 Global Encephalitis Treatment Market Outlook, By Immunoglobulin therapy (2024-2032) ($MN)
Table 10 Global Encephalitis Treatment Market Outlook, By Plasmapheresis (2024-2032) ($MN)
Table 11 Global Encephalitis Treatment Market Outlook, By Other Treatments (2024-2032) ($MN)
Table 12 Global Encephalitis Treatment Market Outlook, By Route of Administration (2024-2032) ($MN)
Table 13 Global Encephalitis Treatment Market Outlook, By Oral (2024-2032) ($MN)
Table 14 Global Encephalitis Treatment Market Outlook, By Parenteral (2024-2032) ($MN)
Table 15 Global Encephalitis Treatment Market Outlook, By Other routes of Administration (2024-2032) ($MN)
Table 16 Global Encephalitis Treatment Market Outlook, By Causative Agent (2024-2032) ($MN)
Table 17 Global Encephalitis Treatment Market Outlook, By Viral (2024-2032) ($MN)
Table 18 Global Encephalitis Treatment Market Outlook, By Autoimmune (2024-2032) ($MN)
Table 19 Global Encephalitis Treatment Market Outlook, By Bacterial (2024-2032) ($MN)
Table 20 Global Encephalitis Treatment Market Outlook, By Other Pathogens (2024-2032) ($MN)
Table 21 Global Encephalitis Treatment Market Outlook, By Distribution Channel (2024-2032) ($MN)
Table 22 Global Encephalitis Treatment Market Outlook, By Hospital Pharmacies (2024-2032) ($MN)
Table 23 Global Encephalitis Treatment Market Outlook, By Online Pharmacies (2024-2032) ($MN)
Table 24 Global Encephalitis Treatment Market Outlook, By Retail Pharmacies (2024-2032) ($MN)
Table 25 Global Encephalitis Treatment Market Outlook, By End User (2024-2032) ($MN)
Table 26 Global Encephalitis Treatment Market Outlook, By Hospitals (2024-2032) ($MN)
Table 27 Global Encephalitis Treatment Market Outlook, By Research Centers (2024-2032) ($MN)
Table 28 Global Encephalitis Treatment Market Outlook, By Clinics (2024-2032) ($MN)
Table 29 Global Encephalitis Treatment Market Outlook, By Specialty Centers (2024-2032) ($MN)
Table 30 Global Encephalitis Treatment Market Outlook, By Other End Users (2024-2032) ($MN)
Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us